Page last updated: 2024-11-05

tranexamic acid and Kidney Failure

tranexamic acid has been researched along with Kidney Failure in 13 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.

Research Excerpts

ExcerptRelevanceReference
" The aims of this study were to characterize the inter-patient variability associated with pharmacokinetic parameters and to recommend a new dosing adjustment based on the BART dosing regimen for CPB patients with chronic renal dysfunction (CRD)."1.42Pharmacokinetic modeling of tranexamic acid for patients undergoing cardiac surgery with normal renal function and model simulations for patients with renal impairment. ( Bies, RR; Jerath, A; Pang, KS; Wąsowicz, M; Yang, QJ, 2015)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (46.15)29.6817
2010's6 (46.15)24.3611
2020's1 (7.69)2.80

Authors

AuthorsStudies
Hulde, N2
Zittermann, A2
Deutsch, MA2
von Dossow, V2
Gummert, JF2
Koster, A2
Makhija, N1
Sarupria, A1
Kumar Choudhary, S1
Das, S1
Lakshmy, R1
Kiran, U1
Fisher, C1
Mo, A1
Warrillow, S1
Smith, C1
Jones, D1
Yang, QJ1
Jerath, A1
Bies, RR1
Wąsowicz, M1
Pang, KS1
Martin, K1
Wiesner, G1
Breuer, T1
Lange, R1
Tassani, P1
Barnum, JL1
Sistino, JJ1
Pasquali, SK1
Li, JS1
He, X1
Jacobs, ML1
O'Brien, SM1
Hall, M1
Jaquiss, RD1
Welke, KF1
Peterson, ED1
Shah, SS1
Jacobs, JP1
Hutton, B1
Joseph, L1
Fergusson, D1
Mazer, CD2
Shapiro, S1
Tinmouth, A1
Mangano, DT1
Tudor, IC1
Dietzel, C1
Bremerich, DH1
Strametz, R1
Kirchner, R1
Moritz, A1
Zwissler, B1
Body, SC1
Mouton, R1
Finch, D1
Davies, I1
Binks, A1
Zacharowski, K1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491]Phase 311,000 participants (Actual)Interventional2018-03-15Completed
DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery[NCT03376061]Phase 497 participants (Actual)Interventional2017-12-21Completed
The Effect of Tranexamic Acid (TXA) on Blood Loss and Transfusion Rates in Burn Wound Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT02753816]25 participants (Actual)Interventional2016-04-30Terminated (stopped due to Study enrollment and goals unable to be reached.)
Influence of Elevated Baseline Serum Creatinine and Body Composition on Acute Kidney Injury in Cardiac Surgery - The InCreAS Trial[NCT02598271]200 participants (Actual)Observational2016-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Hemoglobin

[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum

Interventiongrams per deciliter (Mean)
Tranexamic Acid-1.8
Placebo-1.9

Length of Stay

Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days

Interventiondays (Median)
Tranexamic Acid3
Placebo3

Number of Mothers Who Died or Had Thromboembolic Events (Venous or Arterial), Ischemic Stroke, Myocardial Infarction, New-onset Seizure Activity, or Were Admitted to the Intensive Care Unit for More Than 24 Hours

(NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid35
Placebo32

Number of Participants Who Received Open Label TXA or Other Antifibrinolytic

This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid108
Placebo109

Number of Participants Who Received Surgical or Radiologic Interventions to Control Bleeding and Related Complications

This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid233
Placebo231

Number of Participants Who Received Treatments and Interventions in Response to Bleeding and Related Complications

[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid892
Placebo986

Number of Participants Who Were Transfused With 4 or More Units of Packed Red Blood Cells

Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid20
Placebo19

Number of Participants Who Were Transfused With Other Blood Products

This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid29
Placebo31

Number of Participants Who Were Treated With Uterotonics Other Than Oxytocin

This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid649
Placebo732

Number of Participants With a Thromboembolic Event (Venous or Arterial), Ischemic Stroke, or Myocardial Infarction

[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid12
Placebo13

Number of Participants With Estimated Blood Loss Greater Than 1 Liter During Delivery

[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour

InterventionParticipants (Count of Participants)
Tranexamic Acid339
Placebo368

Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells

Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner

InterventionParticipants (Count of Participants)
Tranexamic Acid201
Placebo233

Number of Participants With Postpartum Infectious Complications

[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid162
Placebo125

Number of Participants With Seizure Activity That Was Not Seen Prior to Study Enrollment

This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid2
Placebo0

Mean Concentration of TxA in Plasma Collected From Participants

Plasma TxA concentrations measured from blood samples taken upon arrival in the ICU (NCT03376061)
Timeframe: on arrival in ICU within 3 hours

Interventionmicrogram per milliliter per kilogram (Mean)
Topical TxA (Intervention)0.58
Intravenous TxA (Control)1.10

Median Number of Hours Participants Spent in ICU

Number of hours participants spent in the intensive care unit (ICU) (NCT03376061)
Timeframe: Number of hours spent in ICU from arrival to exit (collected at the Post-Operative Visit).

Interventionhours (Median)
Topical TxA (Intervention)23
Intravenous TxA (Control)26

Median Volume of Mediastinal Fluid Collected From Participants

Cumulative volume (mL) of fluid collected from mediastinal drainage tubes 24 hours after the surgical procedure (NCT03376061)
Timeframe: Fluid collected in the first 24 hours after the surgical procedure

InterventionmL (Median)
Topical TxA (Intervention)500
Intravenous TxA (Control)540

Number of Participants With Mortality

The occurrence of death due to any cause (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge

InterventionParticipants (Count of Participants)
Topical TxA (Intervention)1
Intravenous TxA (Control)1

Number of Participants With RBC Transfusion

Patients requiring a red blood cell transfusion (NCT03376061)
Timeframe: Intra-operative and post-operative RBC transfusions

InterventionParticipants (Count of Participants)
Topical TxA (Intervention)19
Intravenous TxA (Control)23

Number of Participants With Re-operation for Bleeding or Tamponade

Occurrence of re-operation for the purpose of bleeding or cardiac tamponade (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge

InterventionParticipants (Count of Participants)
Topical TxA (Intervention)0
Intravenous TxA (Control)1

Number of Participants With Seizures

Patients experiencing a post-operative seizure (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge

InterventionParticipants (Count of Participants)
Topical TxA (Intervention)0
Intravenous TxA (Control)1

Blood Transfusion Rates, Defined Nominally (Binary) as Having at Least One Transfusion

To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries. (NCT02753816)
Timeframe: First burn surgery to hospital discharge

InterventionPatients with 1 or more transfusions (Number)
Tranexamic Acid2
Placebo3

Effect of Tranexamic Acid on the Total Length of Hospital Admission for a Large (350 cm2) Burn Injury

To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival. (NCT02753816)
Timeframe: Hospital admission to hospital discharge

InterventionDays (Median)
Tranexamic Acid23
Placebo9

Intraoperative Blood Loss in mL

To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries. (NCT02753816)
Timeframe: Intraoperative, average 122 minutes

InterventionmL (Median)
Tranexamic Acid100
Placebo325

Reviews

1 review available for tranexamic acid and Kidney Failure

ArticleYear
Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.
    BMJ (Clinical research ed.), 2012, Sep-11, Volume: 345

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced

2012

Trials

2 trials available for tranexamic acid and Kidney Failure

ArticleYear
Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety.
    Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:6

    Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aorta, Thoracic; Blood Loss, Surgical; Blood Tran

2013
[Aprotinin in cardiac surgery: more risks than usefulness?].
    Der Anaesthesist, 2006, Volume: 55, Issue:9

    Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Female; Hemostatics

2006

Other Studies

10 other studies available for tranexamic acid and Kidney Failure

ArticleYear
Tranexamic acid and convulsive seizures after off-pump coronary artery bypass surgery: the role of renal insufficiency.
    Interactive cardiovascular and thoracic surgery, 2019, 12-01, Volume: 29, Issue:6

    Topics: Adult; Aged; Antifibrinolytic Agents; Coronary Artery Bypass, Off-Pump; Female; Glomerular Filtratio

2019
Tranexamic acid and convulsive seizures after isolated coronary artery bypass surgery: the role of cardiopulmonary bypass and renal function.
    Interactive cardiovascular and thoracic surgery, 2020, 04-01, Volume: 30, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Glomerular Fi

2020
Utility of thromboelastography in managing acquired Factor VIII inhibitor associated massive haemorrhage.
    Anaesthesia and intensive care, 2013, Volume: 41, Issue:6

    Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Blood Transfusion; Endometrial Neoplasms; Factor

2013
Pharmacokinetic modeling of tranexamic acid for patients undergoing cardiac surgery with normal renal function and model simulations for patients with renal impairment.
    Biopharmaceutics & drug disposition, 2015, Volume: 36, Issue:5

    Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Computer Simulation; Female; Humans; Kidney;

2015
The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients.
    Anesthesia and analgesia, 2008, Volume: 107, Issue:6

    Topics: Adult; Aged; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Coronary Artery Bypass

2008
Renal dysfunction in cardiac surgery: identifying potential risk factors.
    Perfusion, 2009, Volume: 24, Issue:2

    Topics: Aged; Antifibrinolytic Agents; Aprotinin; Cardiopulmonary Bypass; Hemostatics; Humans; Middle Aged;

2009
Comparative analysis of antifibrinolytic medications in pediatric heart surgery.
    The Journal of thoracic and cardiovascular surgery, 2012, Volume: 143, Issue:3

    Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Chi-Square Distribu

2012
The risk associated with aprotinin in cardiac surgery.
    The New England journal of medicine, 2006, Jan-26, Volume: 354, Issue:4

    Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr

2006
The risk associated with aprotinin in cardiac surgery.
    The New England journal of medicine, 2006, Jan-26, Volume: 354, Issue:4

    Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr

2006
The risk associated with aprotinin in cardiac surgery.
    The New England journal of medicine, 2006, Jan-26, Volume: 354, Issue:4

    Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr

2006
The risk associated with aprotinin in cardiac surgery.
    The New England journal of medicine, 2006, Jan-26, Volume: 354, Issue:4

    Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr

2006
Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery.
    Anesthesia and analgesia, 2006, Volume: 103, Issue:6

    Topics: Aminocaproic Acid; Animals; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Drug Hyper

2006
Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study.
    Lancet (London, England), 2008, Feb-09, Volume: 371, Issue:9611

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surg

2008